Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Validation of circulating miRNAs associated with breast cancer subtypes in the MCC-Spain study by RT-qPCR

ABSTRACT: This study represents the validation phase of circulating microRNAs associated with breast cancer detection within the MCC-Spain study. A total of 444 participants (127 cancer-free controls and 317 breast cancer cases) were included. Cases were stratified into molecular subtypes (Luminal A, Luminal B, HER2-positive, and Basal-like) according to St. Gallen criteria. A panel of 46 candidate miRNAs was quantified in serum samples using RT-qPCR (miRCURY LNA technology). Two endogenous miRNAs (let-7d-5p and let-7i-5p) were used for normalization. Differential expression and predictive modeling were performed using normalized and log₂-transformed expression values. This dataset supports subtype-specific and overall breast cancer detection models integrating molecular and epidemiological factors.

ORGANISM(S): Homo sapiens

PROVIDER: GSE320031 | GEO | 2026/02/20

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Analysis of miRNA expression profiling in 3 samples(normal, cigarette smoking and lung cancer population's serum)

Project description:Using the highly sensitive miRNA array, we determined the serum miRNAs profiles of 10 non-smokers, 10 smokers and 10 lung cancer patients by miRCURY LNA™ microRNA Arrays. Differential expressed miRNAs were further validated in a larger scale samples. We found that let-7i-3p and miR-154-5p were significantly downregulation in serum of smokers and lung cancer patients. The serum level of let-7i-3p and miR-154-5p is associated with smoking and smoking-related lung cancer. In this study, we mix 10 samples with equal volume of each group(non-smoking control group,smoking group and lung cancer group ) and run RNA extractions. And then miRCURYTM LNA Array (v.16.0) was applied in the studying of miRNA expression profile and its alteration to gain the miRNA expression profile to compare the variety between each two groups respectively.

2014-06-17 | E-GEOD-58540 | biostudies-arrayexpress

Analysis of miRNA expression profiling in 3 samples(normal, cigarette smoking and lung cancer population's serum)

2014-06-17 | GSE58540 | GEO

Five microRNAs in serum are able to differentiate breast cancer patients from healthy individuals

Project description:Breast Cancer is the cancer with most incidence and mortality in women. microRNAs are emerging as novel prognosis/diagnostic tools. Our aim was to identify a serum microRNA signature useful to predict cancer development. We focused on studying the expression levels of 30 microRNAs in the serum of 96 breast cancer patients versus 92 control individuals. Bioinformatic studies provide a microRNA signature, designated as a predictor, based upon the expression levels of 5 microRNAs. Then, we tested the predictor in a group of 60 randomly chosen women. Lastly, a proteomic study unveiled the over-expression and down-regulation of proteins differently expressed in the serum of breast cancer patients versus that of control individuals. Twenty-six microRNAs differentiate cancer tissue from healthy tissue and 16 microRNAs differentiate the serum of cancer patients from that of the control group. The tissue expression of miR-99a-5p, mir-497-5p, miR-362, and miR-1274, and the serum levels of miR-141 correlated with patient survival. Moreover, the predictor consisting of mir-125b-5p, miR-29c-3p, mir-16-5p, miR-1260, and miR-451a was able to differentiate breast cancer patients from controls. The predictor was validated in 20 new cases of breast cancer patients and tested in 60 volunteer women, assigning 11 out of 60 women to the cancer group. An association of low levels of mir-16-5p with a high content of CD44 protein in serum was found. Circulating microRNAs in serum can represent biomarkers for cancer prediction. Their clinical relevance and use of the predictor here described might be of potential importance for breast cancer prediction.

2020-09-18 | PXD020795 | Pride

Characterization of miRNA expression in 3D cultured cells

Project description:A Comprehensive miRNA-lncRNA-mRNA Corregulation Network in 3D Cultures of Luminal B Breast Cancer Three-dimensional (3D) cell cultures offer advantages over traditional 2D models by better replicating tumor biology. In this study, we examined the effects of 3D culture on miRNA expression in BT-474 luminal B breast cancer cells. Microarray analysis revealed significant differences: 82 miRNAs were upregulated and 119 downregulated in 3D conditions. A regulatory network was constructed involving four miRNAs consistently downregulated (miR‑92a‑3p, miR‑539‑5p, miR‑18a‑5p, miR‑130a‑3p), potentially influencing MAPK signaling, ECM remodeling, and estrogen receptor activity. These results highlight how 3D systems improve understanding of breast cancer biology and may help uncover novel therapeutic targets.

2025-12-03 | GSE299423 | GEO

The analysis of plasma proteomics for luminal A breast cancer

Project description:Breast cancer (BC) is the prevailing malignancy among women, exhibiting a discernible escalation in incidence within our nation, hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) breast cancer is the most common subtype. In this study, we aimed to search for a non-invasive, specific, blood-based biomarker for the early detection of luminal A breast cancer through proteomic studies.

2026-02-06 | PXD074130 |

Tumor Suppressor Role for the c-Myb Oncogene in Luminal Breast Cancer

Project description:The transcription factor c-Myb has been well characterized as an oncogene in several human tumor types, and its expression in the hematopoietic stem/progenitor cell population is essential for proper hematopoiesis. However, the role of c-Myb in mammopoeisis and breast tumorigenesis is poorly understood, despite its high expression in the majority of breast cancer cases (60-80%). We find that c-Myb high expression in human breast tumors correlates with the luminal/ER+ phenotype and a good prognosis. RNAi knock-down of endogenous c-Myb levels in the MCF7 luminal breast tumor cell line increases tumorigenesis both in vitro and in vivo, suggesting a tumor suppressor role in luminal breast cancer. We created a mammary-derived c-Myb expression signature and found it to be highly correlated with a published mature luminal mammary cell signature and least correlated with a mammary stem/progenitor lineage gene signature. These data describe, for the first time, a tumor suppressor role for the c-Myb proto-oncogene in breast cancer that has implications for understanding luminal tumorigenesis and for guiding treatment. refXsample

2010-10-15 | E-GEOD-21371 | biostudies-arrayexpress

RNA sequencing of human breast cancer cells with CUL4B knockdown

Project description:Approximately 30% of cases are resistant to TAM, which has become a major obstacle for breast cancer therapy.In this study, we demonstrated that CUL4B promotes TAM resistance in breast cancer cells through miR-32-5p/ER-α36 axis. CUL4B is overexpressed in TAM-resistant breast cancer cells and positively correlates with the levels of ER-α36 protein in human breast cancer specimens. Mechanistically, CUL4B positively regulates ER-α36 expression by epigenetically repressing the transcription of miR-32-5p. These findings provide not only a mechanistic insight into the role of CUL4B in regulating TAM sensitivity but also a potential target for the therapy of breast cancer.

2022-09-08 | GSE158651 | GEO

POL and Z1031 Gene Expression_Final

Project description:Background: Unlike estrogen receptor (ER) negative breast cancer, ER-positive breast cancer outcomes are less influenced by lymphocyte content, indicating a need for investigation of checkpoint targets and immune tolerance mechanisms that may be specific to this disease subset. Methods: A supervised analysis of microarray data from the Alliance/ACOSOG Z1031 trial was conducted to identify upregulated genes in Luminal B breast cancers that exhibited persistent tumor proliferation despite aromatase inhibitor therapy (33 cases Ki67 >10%) versus Luminal B breast cancers that were more sensitive (33 cases Ki67 <10%). Results: This study identified thirty genes (Pearson’s r>0.4 with Ki67 as a continuous variable). These genes were enriched for immune tolerance processes (p<0.005) and three targetable immune checkpoint components were upregulated in resistant cases: IDO1, LAG3, and PD1. High IDO1 mRNA associated with poor prognosis in ER+ disease across two independent cohorts (METABRIC and TCGA). Furthermore, analysis indicated IDO1 was tightly associated with IFN-γ/STAT1 signaling. As a composite immune tolerance signature, expression of these pathway components associated with higher baseline Ki67 and lower ER, PgR levels and poor disease specific survival. In tissue microarray analysis, IDO1 was observed in stromal cells and tumor-associated macrophages, with a higher incidence in Luminal B cases. Further mRNA and tissue microarray analyses associated IDO1 expression with the presence of macrophages (M1 by CIBERSORT) and regulatory T cells. Conclusion: Targetable immune-checkpoint components are upregulated in majority of neoadjuvant endocrine therapy resistant Luminal B cases. Our findings suggests potential for immune checkpoint inhibitors in poor outcome ER+ breast cancer.

2020-04-13 | GSE136644 | GEO

INTERCELLULAR HIF1alpha REPROGAMS MAMMARY PROGENITORS AND MYELOID IMMUNE EVASION TO DRIVE HIGH-RISK BREAST LESIONS

Project description:The origin of breast cancer, whether primary or recurrent,is unknown. Here, we show that invasive breast cancer cells under conditions of hypoxia release small extracellular vesicles (sEV) that disrupt the differentiation hierarchy of the normal mammary epithelium, expand stem and luminal progenitor cells, and induce atypical ductal hyperplasia, cellular proliferation, and intraepithelial neoplasia. This is accompanied by systemic immunosuppression with increased myeloid cell release of the “alarmin”, S100A9, and multiple oncogenic traits of EMT, sustained angiogenesis, and local and disseminated luminal cell invasion, in vivo. When applied on the genetic background of a driver oncogene (MMTV-PyMT), hypoxic sEV accelerate bilateral breast cancer onset and progression. Mechanistically, genetic or pharmacologic targeting of hypoxia-inducible factor-1 (HIF1) packaged in hypoxic sEV or homozygous deletion of S100A9 normalizes mammary gland differentiation, restores T cell function and prevents atypical hyperplasia. The transcriptome of sEV-induced mammary gland lesions resembles luminal breast cancer, and detection of HIF1 in plasma circulating sEV from luminal breast cancer patients correlates with clinical recurrence. Therefore, a pleiotropic sEV-HIF1 signaling axis drives local and systemic mechanisms of mammary gland transformation at high risk for full-blown, multifocal breast cancer. This pathway may provide a readily accessible biomarker of luminal breast cancer progression.

2023-05-12 | GSE225986 | GEO

RNA sequencing quantitative analysis of exosome miRNAs in plasma in Metastatic renal cell carcinoma (mRCC)

Project description:Purpose: Since clinical characteristics are often inaccurate and subjective, we evaluated the prognostic value of plasma exosomal miRNAs to predict survival in metastatic renal cell cancer (mRCC). Methods: RNA sequencing was performed to identify candidate exosomal miRNAs associated with overall survival in a screening cohort of 41 mRCC patients.Candidate miRNAs were further evaluated for prognosis by TaqMan quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) in a follow-up cohort of 65 mRCC patients. Results: RNA sequencing in screening cohort generated 3.75 million mappable reads per patient, of those with normalized read counts>8 RPM (reads per million), 93.8% were mapped to miRNAs for a total of 322 unique miRNAs. Cox regression analysis identified 20 miRNAs that were associated with overall survival (OS, FDR< 0.05). Among these 20 significant miRNAs, three were validated in a separate independent cohort of 65 patients with mRCC.Patients with lower expression of miR-26a1-3p, miR-let-7i-5p and miR-615-3p had a significantly poorer OS than those with higher expression. Multivariate model by combining miR-let-7i-5p and the Memorial Sloan-Kettering Cancer Center (MSKCC) score significantly improved survival prediction. Conclusions: Our study identifies multiple plasma exosomal miRNAs showing association with survival in mRCC stage patients. Multivariate model by combining miR-let-7i-5p and the Memorial Sloan-Kettering Cancer Center (MSKCC) score significantly improved survival prediction.

2017-10-31 | GSE93175 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data